<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115076</url>
  </required_header>
  <id_info>
    <org_study_id>JKR-0511</org_study_id>
    <nct_id>NCT00115076</nct_id>
  </id_info>
  <brief_title>Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Phase IIIB Study to Evaluate the Mechanism of Action of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is&#xD;
      to study the action and the effects of Efalizumab, on psoriasis. This medication has been&#xD;
      studied extensively and has been found to be effective and safe in the treatment of&#xD;
      psoriasis. The eligible patient will have 10% of his/her body surface area involved with&#xD;
      psoriasis vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eligible patient will receive the drug Efalizumab, weekly for 12 weeks, by injection. The&#xD;
      patient will be seen weekly for 12 weeks and every other week for the 12 weeks of follow up.&#xD;
      At those visits, the patient can expect that a physical and skin exam will be done. At&#xD;
      specific weeks, blood work will be drawn, clinical photography taken and a skin biopsy done.&#xD;
      Two types of skin biopsies will be done after local anesthesia has been administered. One is&#xD;
      a punch biopsy where a small piece of skin will be taken, the approximate size of a pencil&#xD;
      eraser. The second type of skin biopsy is shave biopsy, where a postage sized piece of skin&#xD;
      will be taken.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2003</start_date>
  <completion_date type="Actual">April 6, 2011</completion_date>
  <primary_completion_date type="Actual">May 18, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Improvement of Target Lesions</measure>
    <time_frame>week 12</time_frame>
    <description>a single composite score based on quantitative measurement of epidermal acanthosis, qualitative expression of Keratin16 (histochemistry assessment) and quantitative measurement of K16 mRNA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Overall Clinical Response as Measured by Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Day 0, day 14, day 42, day 84, Days 112, 140, and 168. PASI has been measured at those timepoints but outcome is related to Baseline and Day 84.</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). Clinical response defined as PASI improvement over 75% at week 12.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>psoriasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moderate to severe plaque psoriasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efalizumab</intervention_name>
    <description>24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection</description>
    <arm_group_label>psoriasis</arm_group_label>
    <other_name>Raptiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Signed informed consent&#xD;
&#xD;
          -  Plaque psoriasis covering &gt;10% of total BSA&#xD;
&#xD;
          -  Diagnosis of plaque psoriasis for at least 6 months&#xD;
&#xD;
          -  PASI score &gt;=12 (see Appendix A) or Linear PASI score of &gt;= 8.0 at screening (see&#xD;
             Appendix B)&#xD;
&#xD;
          -  In the opinion of the investigator, candidate for systemic therapy for psoriasis:&#xD;
&#xD;
               -  Who has not been previously treated (naive to systemic treatment) OR&#xD;
&#xD;
               -  Who has had prior treatment with systemic therapy for psoriasis (e.g., PUVA,&#xD;
                  cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate&#xD;
                  mofetil (MMF), thioguanine, hydroxyurea, sirolimus, azathioprine, 6-MP,&#xD;
                  etanercept)&#xD;
&#xD;
          -  Body weight of &lt;140 kg&#xD;
&#xD;
          -  18 to 75 years old. As the risk of Efalizumab in childhood is unknown, those &lt; 18years&#xD;
             will be excluded from the study&#xD;
&#xD;
          -  For women of childbearing potential or in men whose partners may become pregnant,&#xD;
             willingness to use an acceptable method of contraception to prevent pregnancy for the&#xD;
             duration of the study (while receiving study medication and 3 months following).&#xD;
             Acceptable methods of contraception include use of a condom; abstinence; use by sexual&#xD;
             partner of oral implantable or injectable contraceptives, IUD, female condom,&#xD;
             diaphragm with spermicide, cervical cap; or a sterile sexual partner&#xD;
&#xD;
          -  Willingness to hold sun exposure reasonably constant and to avoid use of tanning&#xD;
             booths or other UV light sources during the study&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria are ineligible for study entry:&#xD;
&#xD;
          -  Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanized monoclonal&#xD;
             antibodies or fusion proteins that contain an Ig Fc region&#xD;
&#xD;
          -  Clinically significant psoriasis flare during screening or on the first treatment day&#xD;
&#xD;
          -  Treatment with efalizumab (anti-CD11a) within the last 12 months before enrollment&#xD;
&#xD;
          -  Pregnancy or lactation. As the risk of Efalizumab in pregnancy is unknown, pregnant&#xD;
             women will be excluded from the study&#xD;
&#xD;
          -  History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial&#xD;
             infection&#xD;
&#xD;
          -  History of active tuberculosis (TB) or currently undergoing treatment for TB. PPD&#xD;
             testing or chest X-ray is required for high-risk subjects (see Appendix D).&#xD;
&#xD;
        Subjects with a positive PPD (not due to BCG vaccination) or chest X-ray will be excluded&#xD;
&#xD;
          -  History of opportunistic infections (e.g., systemic fungal infections, parasites)&#xD;
&#xD;
          -  Seropositivity for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Seropositivity for hepatitis B or C virus&#xD;
&#xD;
          -  Hepatic enzymes &gt;3 times the upper limits of normal (ULN)&#xD;
&#xD;
          -  Diagnosis of hepatic cirrhosis, regardless of cause or severity&#xD;
&#xD;
          -  WBC count &lt;4000μL or &gt;14,000/μL&#xD;
&#xD;
          -  Serum creatinine &gt;2 times the ULN&#xD;
&#xD;
          -  Hospital admission for cardiac disease, stroke, or pulmonary disease within the last&#xD;
             year&#xD;
&#xD;
          -  Presence of malignancy within the past 5 years, including lymphoproliferative&#xD;
             disorders. Subjects with a history of fully resolved basal cell or squamous cell skin&#xD;
             cancer may be enrolled&#xD;
&#xD;
          -  History of substance abuse within the last 5 years&#xD;
&#xD;
          -  Any medical condition that, in the judgment of the investigator, would jeopardize the&#xD;
             subject's safety following exposure to study drug Note: Certain medications and&#xD;
             vaccines may not be used for specified periods of time prior to enrollment or at any&#xD;
             time during the treatment period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Krueger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 20, 2005</study_first_submitted>
  <study_first_submitted_qc>June 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2005</study_first_posted>
  <results_first_submitted>November 18, 2020</results_first_submitted>
  <results_first_submitted_qc>February 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2021</results_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin</keyword>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1 patient was not assigned to any arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Psoriasis</title>
          <description>moderate to severe plaque psoriasis&#xD;
Efalizumab: 24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Psoriasis</title>
          <description>moderate to severe plaque psoriasis&#xD;
Efalizumab: 24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>years</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Improvement of Target Lesions</title>
        <description>a single composite score based on quantitative measurement of epidermal acanthosis, qualitative expression of Keratin16 (histochemistry assessment) and quantitative measurement of K16 mRNA.</description>
        <time_frame>week 12</time_frame>
        <population>28 out of 30 participants completed the study. Then clinical improvement was determined only for those 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Psoriasis</title>
            <description>moderate to severe plaque psoriasis&#xD;
Efalizumab: 24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Improvement of Target Lesions</title>
          <description>a single composite score based on quantitative measurement of epidermal acanthosis, qualitative expression of Keratin16 (histochemistry assessment) and quantitative measurement of K16 mRNA.</description>
          <population>28 out of 30 participants completed the study. Then clinical improvement was determined only for those 28.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Overall Clinical Response as Measured by Psoriasis Area and Severity Index (PASI)</title>
        <description>Psoriasis Area and Severity Index (PASI) combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). Clinical response defined as PASI improvement over 75% at week 12.</description>
        <time_frame>Day 0, day 14, day 42, day 84, Days 112, 140, and 168. PASI has been measured at those timepoints but outcome is related to Baseline and Day 84.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoriasis</title>
            <description>moderate to severe plaque psoriasis&#xD;
Efalizumab: 24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Overall Clinical Response as Measured by Psoriasis Area and Severity Index (PASI)</title>
          <description>Psoriasis Area and Severity Index (PASI) combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). Clinical response defined as PASI improvement over 75% at week 12.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.58" spread="17.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.94" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Psoriasis</title>
          <description>moderate to severe plaque psoriasis&#xD;
Efalizumab: 24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (3.0)">aphthous ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (3.0)">pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James G. Krueger MD, PhD</name_or_title>
      <organization>Rockefeller University</organization>
      <phone>212-327-7730</phone>
      <email>kruegej@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

